Stop codon read-through of a methylmalonic aciduria mutation.

Area of Science:

• Biochemistry
• Genetics
• Pharmacology

Background:

• Methylmalonic aciduria is an inherited metabolic disorder often caused by mutations in the methylmalonyl-CoA mutase (MUT) gene.
• Stop codon mutations, leading to truncated proteins, account for a significant portion of MUT gene defects.
• Current treatment options for Methylmalonic aciduria are limited.

Purpose of the Study:

• To investigate the efficacy of stop codon read-through drugs for potential Methylmalonic aciduria treatment.
• To establish and utilize a genomic reporter assay cell line with a specific MUT gene defect.

Main Methods:

• A human MUT gene sequence was modified in a BAC clone to introduce a premature stop codon.
• An enhanced green fluorescent protein (eGFP) reporter gene was inserted in-frame with the MUT gene.
• HeLa cells were transfected to create the genomic reporter assay cell line, which was then treated with various compounds and analyzed via flow cytometry.

Main Results:

• Gentamicin treatment increased reporter protein production by 1.6-fold.
• Combined treatment with gentamicin and G418 synergistically increased methylmalonyl-CoA mutase production 2.0-fold, confirmed by mRNA, flow cytometry, and enzyme activity.
• Other compounds like Zidovudine, Adefovir, and Cisplatin demonstrated some activity in the assay.

Conclusions:

• This study is the first to demonstrate the potential of stop codon read-through drugs for treating Methylmalonic aciduria.
• The developed genomic reporter assay is a valuable tool for screening such drugs.
• Further investigation with animal studies is warranted to explore therapeutic applications.